Скачать или смотреть BioLineRx Ltd. (BLRX) Q1 2025 Earnings – Full Coverage

*BioLineRx Ltd. (BLRX) Q1 2025 Earnings – Full Coverage*

*Key Highlights:*
*Financials* – Q1 revenue $300K USD; net income $5,100K USD; cash $26,400K USD; $300M Effexxa market; no tariff impact.
*Operations* – Effexxa sales $1,400K USD; pancreatic cancer trial ongoing; pipeline expansion; US ops closed.
*Strategy* – CEO Phil Serlin targets in-licensing; CFO Mali Zeevi focuses efficiency; no tariff exposure.
*Outlook* – New asset announcement 2025; pancreatic trial interim 2026; cash runway to H2 2026.

*Timestamps:*
[00:00] – Opening Remarks and Safe Harbor Statement
[01:25] – CEO Update: Strategic Overview (Phil Serlin)
[04:25] – Effexxa and Sickle Cell Progress
[07:23] – Pancreatic Cancer Trial Update
[12:00] – CFO Update: Financials (Mali Zeevi)
[15:40] – CEO Closing Remarks
[16:18] – Q&A Session Begins
[16:29] – Q&A: Financials and Pipeline (Joe Pantginis, H.C. Wainwright)
[21:46] – Q&A: Effexxa Outlook (Justin Walsh, Jones Trading)
[25:34] – Q&A: Milestone Visibility (John Vandermosten, Zacks)

*Keywords:* BioLineRx, Q1 2025 earnings, BLRX, Effexxa, pancreatic cancer, pipeline

*Buy, Hold, or Sell?*
BioLineRx Ltd. (BLRX) is a HOLD. Q1 net income $5,100K USD and cash runway to H2 2026, with Effexxa royalties and pancreatic cancer progress, show potential; pipeline uncertainty and trial timelines suggest caution. No tariff impact due to non-US focus.

*Max Position* – Allocate 1-2% in a diversified portfolio.

*Comment below with your thoughts! Subscribe for more updates!*
*Full Details:* [BioLineRx Investor Relations](https://ir.biolinerx.com)

*Disclaimer:* This video includes segments from the earnings call by BioLineRx Ltd., used solely for educational and informational purposes under fair use (Section 107, US Copyright Act). No affiliation or endorsement by BioLineRx is implied. All rights to the original content remain with the company. For the official call, visit [https://ir.biolinerx.com](https://ir.biolinerx.com). For inquiries or removal requests, contact us at [email protected].